ALL test with LOT rules and updated questions — Desk research brief

Acute Lymphoblastic Leukemia · United States · Build Claims Line of Therapy

Approved · generated 22 Sep 2026, 09:09 UTC · 28 tables, 440 further findings, 27 sources

Stage 1 — Disease & Diagnostic Foundation

Framework steps: Disease definition and natural history; Epidemiology, incidence, prevalence, mortality; Subtype and molecular/cytogenetic classification; Diagnostic criteria and confirmatory workup; Risk stratification and the patient characteristics that drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)

What happens: This stage establishes the foundational disease understanding for acute lymphoblastic leukemia (ALL) in the United States, including epidemiology, lineage and molecular subtype distinctions, presenting features, diagnostic approaches, and key cohort-defining clinical variables used in pediatric, adolescent/young adult …

Expected output: Epidemiology snapshot table (Metric | Value | Stage or subtype | Source) · Subtype / biology breakdown table (Subtype | Approximate share | Notes) · Diagnostic criteria summary (classification, immunophenotype, cytogenetics, molecular, staging) · Diagnostic workup table · Key clinical variables and cohort-defining forks (age, comorbidity, performance status, organ function) · Key takeaways

Further findings

• ALL is defined as “A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation”.Orphanet
• ALL “primarily affects the bone marrow and peripheral blood” but abnormal cells “can infiltrate any organ or tissue”.Orphanet
• ALL “accounts for 75% of all cases of childhood leukemia cases”.Orphanet
• SEER states ALL “is most frequently diagnosed among people aged <20”.National Cancer Institute, Surveillance, Epidemiology, and End Results Program
• CDC reported ALL represents “20% of all cancers diagnosed in persons aged” under 20 years.CDC / NCHS
• CDC reported “3,000 new cases each year” of pediatric ALL in the United States.CDC / NCHS
• CDC reported pediatric ALL incidence “was highest among Hispanics (42.9 per 1 million)”.CDC / NCHS
• CDC reported pediatric ALL rates “were highest in children aged 1–4 years (75.2 per 1 million)”.CDC / NCHS
• CDC reported pediatric ALL incidence “increased during 2001–2008 and remained stable during 2008–2014”.CDC / NCHS
• CDC surveillance used International Classification of Diseases for Oncology, Third Edition codes 9728–9729, 9811–9818, and 9835–9837.CDC / NCHS
• ALL clinical presentation may include “lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage”.Orphanet
• Some ALL patients present with “life-threatening hemorrhage, infection, or respiratory distress”.Orphanet
• AYA patients were described as “a unique population” with distinct “disease behavior compared with other age groups”.American Society of Hematology
• AYA relapsed/refractory ALL patients “experience greater treatment resistance, higher rates of toxicity”.American Society of Hematology
• Adult ALL induction regimens achieve “complete response rates that range from 60% to 90%”.Hematology (Amsterdam, Netherlands)
• Ph-positive ALL patients experienced relapse “at a median of 58 days after the start of therapy”.Hematology (Amsterdam, Netherlands)
• “Most relapses occur in the bone marrow, whereas extramedullary relapse is relatively uncommon”.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
• ALL was described as “essentially a malignant clonal proliferative disorder of hematopoietic stem cells”.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
• PDQ reported pediatric ALL 5-year survival improved “from 60% to approximately 90% for children younger than 15 years”.National Cancer Institute
• PDQ reported adolescent ALL 5-year survival improved “from 28% to more than 75% for adolescents aged 15 to 19 years”.National Cancer Institute
• ZNF384-rearranged B-ALL post-transplant 3-year outcomes were OS 81.9%, LFS 78.7%, CIR 10.0%, and NRM 11.3%.Transplantation and cellular therapy
• ZNF384-rearranged B-ALL showed molecular MRD positivity was not associated with inferior OS, LFS, or CIR.Transplantation and cellular therapy
• “Flow cytometry supports more precise lineage assignment, particularly in ambiguous cases and those with aberrant markers”.The Libyan journal of medicine
• “Morphology demonstrates high agreement with immunophenotyping in the diagnosis of acute leukemia”.The Libyan journal of medicine
• One cohort reported “children accounted for 69.8% of ALL-group cases”.The Libyan journal of medicine
• One cohort reported “81.3% of AML cases were adults”.The Libyan journal of medicine
• Aberrant marker examples included “CD19 positivity in AML and CD2/CD7 co-expression in AML profiles”.The Libyan journal of medicine
• Diagnostic workup excerpts included “Histologic Features”.Open web
• ASH guidance stated allogeneic transplant “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy”.American Society of Hematology
• MRD-based cohorts included “MRD negative patients” and “patients in MRD-positive CR1”.American Society of Hematology
• Treatment regimens “can vary significantly depending on whether they receive care in a pediatric or in an adult setting”.American Society of Hematology
• Pre-transplant MRD in ZNF384-rearranged B-ALL was assessed by “MFC and RT-qPCR targeting ZNF384 fusion transcripts”.Transplantation and cellular therapy
• Discordant MRD categories included “MFC-negative/molecular-positive (MFC-/Mol+) MRD”.Transplantation and cellular therapy
• Ph-positive ALL treatment incorporated imatinib because of “responses observed in monotherapy trials”.Hematology (Amsterdam, Netherlands)
• The supplied documents define acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of …OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• The NCI SEER data state that "Acute lymphocytic leukemia is most common in children, adolescents …OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• The documents state that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and that it represents “20% of all …OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• 58.3% of patients harbored kinase/RAS pathway mutations.” The document also reports survival and relapse-related clinical milestones after allogeneic hematopoietic stem cell transplantation, including “3-year overall survival (OS), leukemia-free …OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• P = 0.806), LFS (66.7% vs 80.5%OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• P = 0.516), or CIR (25.0% vs 7.3%OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• P = 0.255).” The supplied document addresses limited aspects of acute lymphoblastic leukemia (ALL) diagnosis and demographics …OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• The document states that "By immunophenotyping, 42 patients (56.0%) had precursor acute lymphoblastic leukemia (ALL), 32 (42.7%) had acute myeloid leukemia (AML) …OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)
• SEER also reports “5-YearRelative Survival: 73.2% (2016–2022),” and notes that “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20” and “is most common in children, adolescents …National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)
• A CDC report states that "Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States" and that it represents "3,000 new …National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)
• The supplied document discusses treatment response and limited survival information for adult acute lymphoblastic leukemia (ALL), particularly Philadelphia chromosome-positive (Ph-positive) ALL …National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)
• For adult ALL, the document states that "Current multiagent induction regimens result in complete response rates that range from 60% to 90%." For Ph-positive ALL, the document reports …National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)
• The only relevant information available is a World Health Organization indicator for childhood lymphoid leukaemia survival in multiple countries, reporting “Childhood cancer survival for lymphoid leukaemia, age-standardized 5-year …National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)
• No United States observation is included in the supplied material.National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)
• The documents identify clinically relevant lineage-based and molecularly defined subtypes of ALL, particularly B-cell acute lymphoblastic leukemia (B-ALL).Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• The documents also distinguish “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL)” in adults as a treatment-linked subgroup, stating that “Blinatumomab is currently the only targeted agent approved …Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• However, the supplied documents do not comprehensively cover pediatric versus adult ALL classification, T-cell ALL subtypes, the broader immunophenotypic marker landscape, or the full range of cytogenetic and …Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• One study reported that “Of the acute lymphoblastic leukemia cases, 130 cases (79.3%) were B-cell type and 34 cases (20.7%) were T-cell type.” Immunophenotypic markers linked to diagnosis …Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• The supplied document identifies clinically relevant lineage-based subgroups of ALL in adolescents and young adults as “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL)” and also references “T-cell acute …Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• The documents do reference treatment-linked subgrouping for “Mature B-Cell ALL” and “Ph Chromosome–Positive ALL,” and distinguish the need for “Immunohistochemistry and Cytogenetics” in workup.Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• However, the supplied material does not enumerate the full set of B-cell versus T-cell lineage definitions, immunophenotypic markers, cytogenetic abnormalities, molecular alterations, prognostic categories, or modern treatment-segmentation schemas …Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHO
• The supplied document states that “Accurate diagnosis of acute leukemia (AL) is essential for management” and that “Morphological assessment is used in resource-limited settings …The Libyan journal of medicineOrphanetWHO
• The supplied document identifies acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of …The Libyan journal of medicineOrphanetWHO
• It states that “Bone marrow aspiration was done at the time of diagnosis” and that cases “were diagnosed by standard morphology… & cytochemical methods.” The document also references …The Libyan journal of medicineOrphanetWHO
• The supplied documents indicate that the diagnostic workup for acute lymphoblastic leukemia (ALL) includes laboratory studies, bone marrow aspiration and biopsy, histologic evaluation, immunohistochemistry and cytogenetics, radiologic studies …The Libyan journal of medicineOrphanetWHO
• Age-based cohorting is explicitly recognized because “treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting,” and AYAs are …American Society of HematologyHematology (Amsterdam, Netherlands)Transplantation and cellular therapy
• The supplied document discusses measurable residual disease (MRD) and genomic features in a specific subgroup of B-cell acute lymphoblastic leukemia (B-ALL), namely ZNF384-rearranged B-ALL undergoing allogeneic hematopoietic stem …American Society of HematologyHematology (Amsterdam, Netherlands)Transplantation and cellular therapy
• It states that "Pre-transplant MRD was assessed by MFC and RT-qPCR targeting ZNF384 fusion transcripts" and describes discordant MRD categories including "MFC-negative/molecular-positive (MFC-/Mol+) MRD." The document also identifies …American Society of HematologyHematology (Amsterdam, Netherlands)Transplantation and cellular therapy
• National Cancer Institute guidance and that ALL classification and risk stratification are active topics in the literature …American Society of HematologyHematology (Amsterdam, Netherlands)Transplantation and cellular therapy
• Subpopulation segmentation is also relevant for adult Philadelphia chromosome-negative B-cell ALL because outcome data were reported separately for this subgroup.
• The supplied evidence segments ALL populations by age group, lineage, molecular subtype, MRD status, and risk category.
• Claims-based line-of-therapy analyses should preserve biologic and risk subgroup definitions, including B-cell versus T-cell lineage, Philadelphia chromosome status, MRD status, and age setting.
• These cohort-defining forks are directly linked to treatment selection and transplant consideration in the supplied evidence.
• The supplied evidence classifies disease by lineage, molecular subgroup, and treatment-relevant biologic features.
• The supplied materials describe an ALL disease course involving diagnostic confirmation, lineage and molecular classification, MRD-based risk assessment, frontline treatment selection, and escalation for higher-risk or suboptimal responders.
• Claims-based line-of-therapy construction should incorporate transitions driven by MRD status, biologic subgrouping, and response assessment because these factors determine escalation and transplant pathways.

Key takeaways

1. Claims cohorts should segment pediatric, AYA, and adult ALL because incidence, treatment setting, and survival differ by age.
2. Lineage assignment requires immunophenotyping-linked cohort logic distinguishing B-ALL versus T-ALL using marrow and flow cytometry evidence.
3. Molecular subgroup flags should retain Ph-positive, Ph-negative B-ALL, ZNF384 rearrangements, and MRD status because they alter escalation and transplant pathways.
4. Incident ALL algorithms should combine marrow procedures, morphology, flow cytometry, cytogenetics, and lumbar puncture claims to improve diagnostic specificity.

Stage 2 — Guideline-Based Treatment Landscape & Drug/Biologic Universe

Framework steps: Identify governing guidelines and versions; Treatment settings by stage or phase, and the treatment intent (curative vs. palliative) in each; Map first-line and later-line regimens by treatment setting and guideline preference category; Inventory approved, compendia-supported and off-label agents with label indication, approved line, biomarker restriction and approval date; Capture recent approvals, label expansions, and withdrawn or restricted approvals, with dates; Track how guideline recommendations changed over the study period, with dates; Benchmarks by line and regimen: time on treatment, time to next treatment, PFS, and attrition between lines; Classify therapeutic class and mechanism

What happens: This stage establishes the United States guideline-based treatment landscape and authorized therapy universe for Acute Lymphoblastic Leukemia (ALL) through 2026-09-21 using the supplied evidence. It identifies the major guideline bodies and versions referenced in the evidence, summarizes documented treatment phases and subgroup stratification factors, inventories …

Expected output: Guideline bodies and current versions table (Body | Guideline | Current version) · Treatment settings and intent table (Setting | Intent | Guideline-preferred regimens) · Simplified treatment pathway by setting, risk group / branch point and guideline preference category, with the point at which biomarker testing is expected · Drug and biologic inventory (Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code) · Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates) · Guideline change log (Date | Body | Change) · Line-of-therapy benchmarks table (Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source) · Key takeaways

Further findings

• NCCN adult ALL guidance focuses on adults with newly diagnosed Ph-negative ALL and treatment strategies for Ph-positive and Ph-negative disease in AYA and adults.Journal of the National Comprehensive Cancer Network : JNCCN
• NCCN pediatric ALL guidance addresses risk assessment and risk-adapted therapy for BCR::ABL1-negative, BCR::ABL1-positive, T-cell lineage, and infant ALL.Journal of the National Comprehensive Cancer Network : JNCCN
• Treatment decisions are influenced by age, Philadelphia chromosome/BCR::ABL1 status, cell origin, CD20 expression, cytogenetic factors, and MRD status.Open web
• BCR-ABL TKIs are described as the backbone of care in Ph-positive B-cell ALL; second- or third-generation TKIs preferred over imatinib.Open web
• Poor-risk biomarkers cited include BCR::ABL1-like ALL, IKZF1 alterations, TP53 mutation, KMT2A rearranged disease, and BCR::ABL1 with IKZF1 plus antecedent CML.Open web
• Standard-risk biomarker category cited includes t(9;22)(q34;q11.2): BCR::ABL1 without IKZF1 and without antecedent chronic myeloid leukemia.Open web
• Ph-like ALL is described as a high-risk B-ALL subgroup with high chemotherapy resistance and relapse rates.Journal of Clinical Oncology
• Ph-like ALL lacks BCR-ABL1 rearrangement but has activated cytokine receptor and kinase signaling similar to Ph+ ALL.Journal of Clinical Oncology
• CRLF2-rearranged Ph-like ALL may be identified by increased TSLPR surface expression using flow cytometric immunophenotyping.Journal of Clinical Oncology
• Specific CRLF2 rearrangements in Ph-like ALL can be confirmed by genetic testing.Journal of Clinical Oncology
• Adult ALL induction commonly uses prednisone, vincristine, and an anthracycline, with optional asparaginase or cyclophosphamide additions.National Cancer Institute
• Imatinib incorporation into relatively standard chemotherapy for newly diagnosed adult Ph-positive ALL may provide significant survival advantage.National Cancer Institute
• Reported induction components included vincristine, corticosteroid, pegaspargase or calaspargase pegol, with or without anthracycline.Journal of Clinical Oncology
• Ponatinib approval regimen used 6 consolidation cycles alternating methotrexate and cytarabine.FDA
• Ponatinib approval regimen used 11 maintenance cycles with vincristine and prednisone.FDA
• Ponatinib dose reduction to 15 mg once daily occurred after induction completion and MRD-negative complete remission.FDA
• ASH relapsed/refractory guidance addressed immunotherapy, targeted therapies, allogeneic HSCT, and CNS-directed therapy.Blood advances
• Allogeneic SCT recommendations cited for children in CR2 after early marrow relapse in precursor-B ALL.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
• Salvage regimens for relapsed or primary refractory adult ALL are generally cytarabine-based combinations.Journal of Clinical Oncology
• One adult relapsed/refractory regimen evaluated cytarabine 100 mg/m2 continuous infusion for seven days plus idarubicin 12 mg/m2 days 1-3.Journal of Clinical Oncology
• FLAM regimen identified for relapsed/refractory adult ALL used fludarabine, cytarabine, and mitoxantrone.M.D. Anderson Cancer Center
• Venetoclax-containing regimens reported in relapsed/refractory T-ALL/T-LBL included monotherapy, hypomethylating agents, chemotherapy, nelarabine, targeted agents, and navitoclax.American Society of Hematology
• In one venetoclax-based relapsed/refractory T-ALL/T-LBL series, 21% proceeded to allo-HCT.American Society of Hematology
• Daratumumab-hyaluronidase was studied for persistent or recurrent MRD after chemotherapy in T-cell ALL.Journal of Clinical Oncology
• CD19-directed CAR-T therapies produced dramatic responses in more than 70% of relapsed/refractory B-ALL patients in cited literature.Journal of Clinical Oncology
• Up to 50% of patients achieving remission after CD19 CAR-T subsequently relapse in cited literature.Journal of Clinical Oncology
• Post-CAR-T monitoring protocols cited flow cytometry MRD-negative assessment within 42 days after infusion.National Cancer Institute (NCI)
• Treatment selection after relapse considers disease burden and candidacy for future consolidative therapy including allo-HSCT.Blood advances
• The evidence reviewed did not identify explicit ALL approval withdrawals, suspensions, or accelerated-approval reversals.US Food and Drug Administration
• The NCCN adult guideline states that it focuses on “treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence,” and describes “treatment strategies for Philadelphia …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• The supplied documents identify major guideline bodies and some high-level frontline management recommendations for acute lymphoblastic leukemia (ALL) …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• The 2026 ASH guideline for adolescents and young adults (AYAs) states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• One document describes a clinical trial in newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL using “blinatumomab with dasatinib or imatinib and standard chemotherapy,” …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• It does report an FDA approval relevant to newly diagnosed Philadelphia chromosome-positive ALL in adults: “On March 19, 2024, the Food and Drug Administration granted accelerated approval to …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• The documents do identify two guideline-related recommendations: the 2026 American Society of Hematology (ASH) guideline for adolescents and young adults (AYAs) with relapsed/refractory ALL states that “Key recommendations …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• No document supplies complete first-line induction, consolidation, maintenance, or MRD-positive regimen algorithms, preference levels, or full patient/disease subgroup categorizations.Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• The NCI PDQ document also states that imatinib is generally incorporated for Ph-positive ALL and that allogeneic bone marrow transplant should be considered when a suitable donor is …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• The American Society of Hematology published “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” specifically addressing “frontline management …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of Hematology
• The supplied documents identify that major guidelines addressing relapsed/refractory ALL in the United States include the 2026 ASH guidelines for adolescents and young adults (AYAs) with relapsed/refractory ALL …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The ASH guideline states that its recommendations cover “remission reinduction and consolidation” and focus on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• One study states that in relapsed or refractory adult ALL, “Salvage regimens in these patients and in patients with primary refractory disease are generally based on cytarabine in …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• One evidence-based review states that for pediatric ALL, "Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The documents do contain limited information about relapsed/refractory (R/R) ALL biomarker-defined populations and prior therapy considerations in a revumenib study, including "Documented R/R ALL/MPAL with KMT2A rearrangement" and …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The documents also discuss Philadelphia chromosome-positive (Ph+) ALL and tyrosine kinase inhibitors (TKIs), stating that "Targeting of BCR-ABL with tyrosine kinase inhibitors (TKIs) has resulted in rapid clinical …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The documents do contain limited information that CAR-T cells are used in relapsed/refractory B-cell acute lymphoblastic leukemia in children, adolescents …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The documents do contain limited information relevant to relapsed/refractory T-cell ALL/T-cell lymphoblastic lymphoma (T-ALL/T-LBL), including an FDA-labeled later-line indication for nelarabine after at least two prior chemotherapy regimens …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The supplied documents do not contain major clinical guideline recommendations, guideline preference categories, treatment-setting stratification, later-line regimen sequencing, biomarker subgroup guidance beyond Philadelphia chromosome positivity, or recommendations regarding …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The documents also identify ponatinib (ICLUSIG) and dasatinib (SPRYCEL/Dasatinib tablets) FDA applications/products, but they do not provide clinical guideline preference categories or regimen recommendations.Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• The documents do contain limited information about therapies studied or compared in relapsed/refractory ALL, including CD19-directed CAR-T therapy, tisagenlecleucel, blinatumomab, clofarabine-based regimens, and investigational venetoclax-containing therapy for T-ALL/T-LLy.Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• They also reference transplant and cell therapy use, including that tisagenlecleucel was evaluated "with use as a bridge to transplant" and that patients in a T-ALL/T-LLy study "must …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• One document references treatment agents in relapsed or refractory ALL, specifically “blinatumomab” and “inotuzumab ozogamicin” in adults “receiving zero or one prior salvage therapy.” Another guideline-oriented document discusses …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• It does provide FDA information confirming that TECARTUS (brexucabtagene autoleucel), a cell therapy, is indicated in the United States for “Adult patients with relapsed or refractory B-cell precursor …Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical Oncology
• Approval: 2006” for dasatinib, and the Gleevec NDA record lists “Application: NDA021588 sponsored by NOVARTIS” with product strengths “EQ 100MG BASE” and “EQ 400MG BASE.” The documents do …Apotex CorpBluePoint LaboratoriesNOVARTIS
• Imatinib mesylate is labeled for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The documents consistently restrict the ALL indications to “Philadelphia chromosome positive (Ph+)” disease, but they do not provide HCPCS, NDC, J-codes, ICD-10, or other claims-relevant coding identifiers.Apotex CorpBluePoint LaboratoriesNOVARTIS
• Approval: 2004," and one label specifies that "This indication is based upon response rate" and that "There are no trials verifying an improvement in disease-related symptoms or increased …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The document specifically states that the guideline recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The supplied documents discuss investigational and commercial-use contexts for tisagenlecleucel (CTL019) and investigational CD19 CAR-T therapies in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The supplied documents identify three FDA-approved drugs for Acute Lymphoblastic Leukemia (ALL): clofarabine injection, mercaptopurine oral suspension, and methotrexate injection.Apotex CorpBluePoint LaboratoriesNOVARTIS
• Biomarker-related restrictions are only described for mercaptopurine, where TPMT and NUDT15 deficiency are addressed through dosage modifications.Apotex CorpBluePoint LaboratoriesNOVARTIS
• The documents identify several FDA-regulated products associated with Acute Lymphoblastic Leukemia (ALL), but they do not provide a complete list of all FDA-approved or authorized drugs, biologics …Apotex CorpBluePoint LaboratoriesNOVARTIS
• Approval: 1953.” ARRANON (nelarabine) and SPRYCEL (dasatinib) are identified in FDA Drugs@FDA records with NDA numbers and approval/submission histories, including original approval dates of “2005-10-28” for ARRANON and …Apotex CorpBluePoint LaboratoriesNOVARTIS
• One FDA labeling document states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The supplied documents discuss several therapies used or studied in acute lymphoblastic leukemia (ALL), including rituximab, inotuzumab ozogamicin, blinatumomab …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The documents specifically describe inotuzumab ozogamicin as producing responses in relapsed/refractory ALL, blinatumomab as active in minimal residual disease and relapsed/refractory settings …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The documents also do not provide approval dates, labeled indications, treatment-line specifications, biomarker restrictions for specific FDA-approved products, or claims-relevant coding identifiers.Apotex CorpBluePoint LaboratoriesNOVARTIS
• The documents do state that recommendations are based on factors such as “Philadelphia chromosome status and age” and mention that “targeted agents in frontline therapy is increasingly supported,” …Apotex CorpBluePoint LaboratoriesNOVARTIS
• They do contain disease-setting and biomarker details for clinical trial populations, including Philadelphia chromosome positive (Ph+), ABL-class Philadelphia chromosome-like (Ph-like), CD19-positive, Philadelphia-negative, and KMT2A-rearranged ALL populations.Apotex CorpBluePoint LaboratoriesNOVARTIS
• The supplied document discusses asparaginase-containing regimens for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) and states that "The results of these studies have informed updates to the National Comprehensive Cancer …Apotex CorpBluePoint LaboratoriesNOVARTIS
• One document describes an interventional study of blinatumomab in newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, specifically in adults who are in complete remission or complete …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The study compares subcutaneous versus continuous intravenous blinatumomab used with chemotherapy.Apotex CorpBluePoint LaboratoriesNOVARTIS
• The labeling states that “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and provides dosing for “Metastatic Disease, Leukemia, or Lymphoma” including both single-agent and combination-therapy …Apotex CorpBluePoint LaboratoriesNOVARTIS
• The documents describe treatment pathway differences for adult Philadelphia chromosome (Ph)-positive ALL versus general adult ALL induction therapy …National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• For adult ALL, "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine …National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem …National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• It does describe a high-risk subgroup, stating that “Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subgroup of B-ALL associated with high rates of chemotherapy resistance and …National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, age-group-specific pathways, biomarker testing timepoints, or other risk-segment treatment differences.National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• It only addresses venous thromboembolism management in children with ALL and identifies certain high-risk subgroups during induction, including “T-cell ALL, adolescents older than 10years, overweight patients.” The document …National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• Treatment decisions are described as being influenced by “Age,” “Philadelphia chromosome (Ph)( BCR::ABL1_) status and other cytogenetic factors,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and …National Cancer InstituteNational Cancer Institute (NCI)American Society of Hematology
• Dasatinib labeling states that it is indicated for “adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” and for “pediatric …BluePoint LaboratoriesNOVARTISAlembic Pharmaceuticals Limited
• For SPRYCEL (NDA021986), recent actions included “SUPPL 28 AP 2024-07-31 Labeling STANDARD,” “SUPPL 27 AP 2023-02-08 Labeling STANDARD,” and an earlier “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For …BluePoint LaboratoriesNOVARTISAlembic Pharmaceuticals Limited
• Approval: 2006.” The provided document identifies existing FDA-labeled indications for imatinib mesylate in Acute Lymphoblastic Leukemia (ALL), including “Adult patients with relapsed or refractory Philadelphia chromosome positive acute …BluePoint LaboratoriesNOVARTISAlembic Pharmaceuticals Limited
• It states that NDA219097 for "IMKELDI SOLUTION ORAL strength EQ 80MG BASE/ML" received an approval on "2024-11-22" as a "Type 3 - New Dosage Form STANDARD" application sponsored …BluePoint LaboratoriesNOVARTISAlembic Pharmaceuticals Limited
• For remission induction in adult ALL, the NCI PDQ states that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• In the newly diagnosed infant ALL setting, a phase II trial evaluated “the addition of venetoclax and/or blinatumomab to usual chemotherapy” in “infants with newly diagnosed acute lymphoblastic …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The NCCN adult ALL guideline "focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence," while the pediatric NCCN guideline focuses on "treatment …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The supplied documents describe some therapies and treatment settings for acute lymphoblastic leukemia (ALL), including frontline and resistant/intolerant Philadelphia chromosome-positive (Ph+) ALL settings …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• Blinatumomab was studied in pediatric “relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)” including patients with “refractory, ≥ 2 relapses or relapse after transplant ,” corresponding to later-line/high-risk treatment …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• One document states that “CD19 CAR therapy” has shown “remarkable clinical outcomes in adults and children with ALL” and may “become part of the armamentarium for B cell-ALL,” …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• Another document describes “asparaginase-containing regimens” and “pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute lymphoblastic leukemia/lymphoblastic lymphoma,” but without coding …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The supplied documents identify methotrexate as a therapy used for Acute Lymphoblastic Leukemia (ALL) in a defined treatment context: "treatment of adults and pediatric patients with acute lymphoblastic …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The supplied document provides treatment regimens and treatment phases for adult acute lymphoblastic leukemia (ALL), including induction, consolidation/post-remission …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The document describes induction regimens such as VDP, VIP, VD(C)LP, Hyper-CVAD, CD20 monoclonal antibody combinations, and post-remission use of CD19/CD3 bispecific antibody therapy (blinatumomab), including settings such as …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The supplied documents identify doxorubicin (including Adriamycin formulations) as a therapy indicated for Acute Lymphoblastic Leukemia (ALL).National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The documents state that “Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia” and similarly that “Doxorubicin is indicated for the treatment of acute …National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug Administration
• The supplied documents describe 2026 American Society of Hematology (ASH) guideline recommendations for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory management …American Society of HematologyNational Cancer InstituteOpen web
• The 2026 frontline guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents …American Society of HematologyNational Cancer InstituteOpen web
• In February 2026, ASH published new clinical practice guidelines for adolescents and young adults with ALL, including recommendations favoring “Pediatric-inspired regimens over traditional adult-inspired protocols,” emphasizing “Asparaginase as …American Society of HematologyNational Cancer InstituteOpen web
• The supplied literature is a 2026 ASH guideline for frontline management of acute lymphoblastic leukemia in adolescents and young adults (AYAs) …American Society of HematologyNational Cancer InstituteBlood advances
• The document instead describes a biomarker-guided post-CAR-T monitoring study in pediatric and young adult relapsed B-ALL, and reports only limited remission-related outcome context.American Society of HematologyNational Cancer InstituteBlood advances
• Specifically, it states that after CAR-T therapy, remission “may cure up to 50% of people who receive this therapy,” while also noting “dismal outcomes for patients who experience …American Society of HematologyNational Cancer InstituteBlood advances
• The document instead describes eligibility, follow-up duration, and general response observations for a first-in-human CAR T-cell trial in recurrent or refractory CRLF2/TSLPR-overexpressing B-ALL.American Society of HematologyNational Cancer InstituteBlood advances
• The supplied document discusses relapsed B-cell acute lymphoblastic leukemia (B-ALL) populations receiving CD19 CAR T-cell therapy and subsequent consideration of hematopoietic cell transplantation (HCT) …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• The document does identify relapse after CAR T-cell therapy as a major driver for subsequent treatment escalation, stating that “for people who relapse after CART, it can be …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• The supplied document discusses relapsed/refractory acute lymphoblastic leukemia (ALL) management in adolescents and young adults (AYAs) …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• The document does identify factors associated with relapse/refractory disease and treatment progression, stating that AYAs with relapsed/refractory ALL “experience greater treatment resistance” and “higher rates of toxicity.” It …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• The document does describe factors associated with treatment challenges and decision-making in later-line therapy, stating that AYAs with relapsed/refractory ALL “experience greater treatment resistance” and “higher rates of …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• The supplied documents do not report proportions of United States acute lymphoblastic leukemia patients who advance from first-line to second-line or later therapies, nor do they quantify attrition …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• The documents do mention factors associated with outcomes and treatment decisions, including that survival rates “can vary depending on age, disease subtype, genetic features …National Cancer Institute (NCI)American Society of HematologyNational Cancer Institute
• Therapeutic modalities identified include multiagent chemotherapy, tyrosine kinase inhibitors for Ph+ ALL, immunotherapy, CAR-T therapy, transplant approaches, and lineage-specific agents.
• The evidence supports mapping treatment journeys across induction, consolidation, maintenance, and reinduction phases.
• The supplied evidence identifies NCCN adult ALL guidelines Version 2.2024, NCCN Pediatric ALL guideline Version 2.2025, and ASH 2026 ALL guidelines as major U.S. standards governing treatment selection.
• Guideline-driven cohort logic should incorporate biomarker testing and MRD assessment at diagnosis and during treatment transitions because treatment branching depends on these factors.
• NCCN and ASH pathway structure ALL across treatment phases Pretreatment, induction, consolidation, maintenance therapy, and allogeneic HSCT decision points guided by biomarker and
• Frontline versus relapsed/refractory distinctions are essential because several approvals are limited to specific lines and subpopulations.
• The discovery phase established that Acute Lymphoblastic Leukemia treatment pathways, outcomes, and regulatory positioning are highly stratified by age group, lineage subtype, Philadelphia chromosome/BCR::ABL1 status, molecular subgroup, MRD …
• Downstream modelling should preserve ALL subpopulation stratification variables and setting-specific treatment branches because diagnostic classification, guideline pathways …
• The supplied evidence segments ALL populations by age group, lineage, molecular subtype, MRD status, and risk category, with B-cell lineage disease representing 79.3% of cases and T-cell lineage …
• Diagnostic classification frameworks rely on bone marrow assessment, morphology, cytochemical testing, immunophenotyping, cytogenetics, and lumbar puncture evaluation, with lineage assignment supporte
• The supplied evidence identifies molecular subgrouping that includes Philadelphia chromosome-negative B-cell ALL and ZNF384-rearranged B-ALL with EP300::ZNF384 and TCF3::ZNF384 fusion partners.

Key takeaways

1. Line-of-therapy algorithms should branch by Ph/BCR::ABL1 status, lineage subtype, age group, MRD status, CAR-T exposure, and transplant exposure.
2. MRD testing appears during treatment transitions and post-CAR-T monitoring; cohort logic should capture repeated MRD assessments.
3. Claims mapping requires separate handling for frontline Ph+ TKI regimens, relapsed/refractory immunotherapy, CAR-T, and transplant pathways.
4. Coding enrichment remains incomplete because supplied evidence lacks comprehensive HCPCS, J-code, CPT, and NDC mappings.

Stage 3 — Claims Code Universe: Diagnosis & Procedures

Framework steps: Diagnosis code universe (ICD-10-CM, ICD-9-CM, ICD-11); Procedure, test and encounter codes: diagnostic evidence, non-drug treatment (surgery, radiation, transplant, CAR-T), drug administration, clinical-trial participation; Laboratory and molecular testing codes (LOINC, CPT); Disease-state coding conventions: suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history; Observability limitations

What happens: This stage establishes the observable diagnosis, laboratory, and procedure-code universe for Acute Lymphoblastic Leukemia (ALL) in United States claims data through 2026-09-21 using the supplied evidence. The stage identifies ICD-9-CM and ICD-10-CM leukemia diagnosis concepts tied to active disease, remission, and relapse states …

Expected output: Three-system diagnosis code crosswalk (ICD-9-CM legacy | ICD-10-CM current | ICD-11 stem + extension | Description | Effective and retirement dates) · Disease-state code variants (suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history Z85) · ICD-11 extension codes for molecular subtypes, layered onto the disease stem · Diagnostic test, procedure and non-drug treatment code universe (Category | Example codes | Purpose) · Drug administration and clinical-trial participation codes (Code | Use | Note) · Monitoring signal table · Observability limitations

Further findings

• CMS ICD-10-CM release files list parent concept "C910 — Acute lymphoblastic leukemia " with subcodes C9100, C9101, and C9102.CMS ICD-10-CM Release Files
• ICD-9-CM code 20420 is defined as "Subacute lymphoid leukemia, without mention of having achieved remission."U.S. National Library of Medicine
• ICD-9-CM code 20421 is defined as "Subacute lymphoid leukemia, in remission."U.S. National Library of Medicine
• ICD-9-CM code 20422 is defined as "Subacute lymphoid leukemia, in relapse."U.S. National Library of Medicine
• ICD-9-CM code 20481 is defined as "Other lymphoid leukemia, in remission."U.S. National Library of Medicine
• ICD-9-CM code 20482 is defined as "Other lymphoid leukemia, in relapse."U.S. National Library of Medicine
• ICD-9-CM code 20491 is defined as "Unspecified lymphoid leukemia, in remission."U.S. National Library of Medicine
• ICD-9-CM code 20492 is defined as "Unspecified lymphoid leukemia, in relapse."U.S. National Library of Medicine
• The 2026 ICD-10-CM update documentation displays annual continuity for "20162017201820192020202120222023202420252026."Open web
• LOINC 87008-9 is defined as "Guidance for fluid aspiration of Bone marrow."U.S. National Library of Medicine
• LOINC 30912-0 is defined as "DNA index in Specimen by Flow cytometry (FC)."U.S. National Library of Medicine
• LOINC 26028-1 is defined as "HLA-B27 by Flow cytometry (FC)."U.S. National Library of Medicine
• FISH panels referenced genomic targets "t(9;22) (BCR/ABL1), 11q23.3 (KMT2A, formerly MLL), t(12;21) (ETV6/RUNX1)."Open web
• Companion testing with chromosome analysis was recommended alongside ALL FISH testing.Open web
• The supplied materials identified HCPCS category wording for "Administrative, Miscellaneous and Investigational" services.Open web
• Longitudinal line-of-therapy analyses may use diagnosis-state transitions between C91.00, C91.01, and C91.02 as monitoring signals.CMS ICD-10-CM Release FilesU.S. National Library of Medicine
• Procedure and laboratory utilization may provide observable diagnostic and disease-monitoring signals when direct treatment-intent coding is incomplete.U.S. National Library of MedicineOpen web
• Claims-based ALL analytics in this evidence set rely heavily on proxy signals rather than direct treatment coding.CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• Missing subtype, procedure, and trial-participation visibility may limit cohort specificity and treatment-pathway reconstruction.CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• The CMS ICD-10-CM release files list "C9100 — Acute lymphoblastic leukemia not having achieved remission," "C9101 — Acute lymphoblastic leukemia, in remission," and "C9102 — Acute lymphoblastic leukemia …CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• The supplied documents identify ICD-9-CM acute lymphoid leukemia diagnosis codes for three disease-status categories: active disease without remission, remission, and relapse.CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• The supplied documents identify ICD-9-CM leukemia codes for subacute lymphoid leukemia with distinct disease-status modifiers relevant to claims classification.CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• The only coding information provided is an ICD-9-CM entry stating that code 20491 is defined as "Unspecified lymphoid leukemia, in remission." The supplied documents identify the primary ICD-10-CM …CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• The documents include LOINC 33721-2 for a "Bone marrow Pathology biopsy report," LOINC 48807-2 for a "Bone marrow aspiration report," and LOINC 69052-9 for "Flow cytometry specialist review …U.S. National Library of Medicine
• The only procedure-related coding information provided is a LOINC entry for flow cytometry: LOINC code 107079-6, defined as "Blasts/Cells in Blood by Flow cytometry (FC)." It only identifies …U.S. National Library of Medicine
• The supplied documents identify three LOINC laboratory codes relevant to flow cytometry testing that may be used in hematologic malignancy evaluation and monitoring.U.S. National Library of MedicineOpen web
• The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or ALL-specific monitoring assay coding beyond these LOINC entries.U.S. National Library of MedicineOpen web
• LOINC code 61123-6 is defined as "Lymphocytes/Leukocytes in Specimen by Flow cytometry (FC)." Additional LOINC mappings include 33721-2 for a "Bone marrow Pathology biopsy report" and 48807-2 for …U.S. National Library of MedicineOpen web
• The available document states that LOINC code 104548-3 corresponds to "Monocytes [#/volume] in Blood by Flow cytometry (FC)." The supplied documents do not provide CPT codes, cytogenetic testing …U.S. National Library of MedicineOpen web
• The only laboratory mapping identified is the LOINC code 26028-1, defined as "HLA-B27 by Flow cytometry (FC)." The documents identify several CPT codes for fluorescence in situ hybridization …U.S. National Library of MedicineOpen web
• The documents also state that "FISH is useful to identify chromosome abnormalities in patients with pediatric or adult acute lymphoblastic leukemia (ALL) for diagnostic and prognostic purposes as …U.S. National Library of MedicineOpen web
• The documents state that “The ICD-10 code for acute lymphoblastic leukemia is C91.0, with specific codes for remission status,” and list the ICD-10-CM remission-status concepts “C91.00,” “C91.01,” and …CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• The documents only establish that HCPCS includes categories related to “Administrative, Miscellaneous and Investigational” services and that CMS maintains annually updated CPT/HCPCS code lists through 2026.CMS ICD-10-CM Release FilesU.S. National Library of MedicineOpen web
• Claims-based ALL cohorts can be stratified by disease state using explicit remission and relapse diagnosis coding.
• Procedure and laboratory utilization can provide observable diagnostic and disease-monitoring signals in claims-linked datasets when direct treatment-intent coding is incomplete.
• International harmonization and molecular subtype representation remain limited because ICD-11 mappings were not identified.
• The supplied evidence documents multiple claims observability gaps affecting ALL cohort construction and line-of-therapy inference.
• Procedure-code coverage is incomplete because the evidence set does not include comprehensive CPT, HCPCS, or ICD-10-PCS coding for leukapheresis, stem-cell transplantation workflows, conditioning regi

Key takeaways

1. Cohort logic must map legacy ICD-9-CM lymphoid leukemia remission and relapse variants into ICD-10-CM ALL status groupings.
2. Longitudinal monitoring logic should combine diagnosis transitions with repeated marrow, flow-cytometry, and FISH utilization signals.
3. Line-of-therapy reconstruction must tolerate absent chemotherapy-administration, CAR-T, transplant, and radiation procedure coding.
4. Subtype stratification cannot depend on ICD-11 extensions or comprehensive molecular billing coverage in supplied evidence.

Open items

• In United States claims-oriented coding references through 2026-09-21, which ICD-11 extension codes can be layered onto Acute Lymphoblastic Leukemia stem codes to represent molecular …
• In United States claims data through 2026-09-21, which CPT and HCPCS drug administration procedure codes provide evidence of systemic anti-cancer treatment exposure for Acute …

Stage 4 — Treatment Sequencing, Regimen Library & Code Mapping

Framework steps: Define line-of-therapy (LOT) rules; Build the regimen library by line and phase; Map regimen components to HCPCS/J-codes and NDC; Separate pharmacy from medical benefit claims; Define supportive-care exclusions and ambiguity rules

What happens: This stage establishes the evidence-supported building blocks needed for Acute Lymphoblastic Leukemia treatment-sequencing analyses in U.S. claims data, including limited operational cycle logic, identifiable regimen components, HCPCS/J-code mappings, representative NDC examples, administration and dosing references …

Expected output: Line-of-therapy trigger rules (Trigger | Interpretation) · Regimen library (Regimen | Setting | Components) · Component and HCPCS/J-code mapping (Component drug | HCPCS code | Biosimilar / NDC considerations) · NDC universe (Agent | Representative NDCs | Labeler | Coverage note) with a method note for an exhaustive pull · Dosing and administration reference (Agent | Standard adult dosing | Route / schedule | Key administration notes) · Supportive-care and non-therapeutic exclusion list · Ambiguity rules (pharmacy vs medical benefit, same-drug different-intent)

Further findings

• The supplied document contains treatment-cycle and interruption rules for BESPONSA in relapsed or refractory acute lymphoblastic leukemia, including cycle start timing, dose scheduling, interruption thresholds …National Library of Medicine (DailyMed)
• The supplied documents identify several Acute Lymphoblastic Leukemia regimen component drugs and branded products, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents identify oral and intravenous ALL therapies, but they do not discuss United States claims adjudication under pharmacy versus medical benefit, dual-channel billing, or line-of-therapy routing ambiguities.US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied documents identify some supportive or prophylactic agents associated with acute lymphoblastic leukemia care …US Food and Drug AdministrationBulletin du cancerJournal of the National Comprehensive Cancer Network : JNCCN
• BLINCYTO interruptions due to adverse reactions that are 7 days or less may continue within the same cycle.
• Methotrexate sodium J9250 and J9260 Multiple formulations and manufacturers identified Both oral and injectable formulations identified Potential same-drug different-intent ambiguity across maintenance and meningeal prophylaxis contexts
• It states that "Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission …National Library of Medicine (DailyMed)
• The document does not provide United States claims-data operational algorithms for constructing lines of therapy, including regimen-level line advancement triggers, treatment-gap definitions in claims data, maintenance handling, relapse/re-treatment …National Library of Medicine (DailyMed)
• The supplied document does not describe United States claims-data algorithms for constructing lines of therapy in Acute Lymphoblastic Leukemia, including regimen start/stop logic, line advancement triggers, treatment gaps …National Library of Medicine (DailyMed)
• It only provides BLINCYTO treatment-cycle schedules and interruption rules that mention induction, consolidation, continued therapy, treatment-free intervals, and restarting cycles after interruptions.National Library of Medicine (DailyMed)
• The supplied documents do not provide a comprehensive United States claims-based regimen library for Acute Lymphoblastic Leukemia (ALL) …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The documents do identify several ALL-related therapeutic agents and cellular therapies that may appear in regimen libraries, including “rituximab,” “blinatumomab,” “inotuzumab ozogamicin,” “vincristine sulfate,” “doxorubicin hydrochloride,” “cyclophosphamide,” “methotrexate …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The supplied documents do not provide a comprehensive United States clinical practice or claims-based regimen library for Acute Lymphoblastic Leukemia (ALL) …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The documents do identify several therapies used in relapsed or refractory ALL and transplant-related settings, including "blinatumumab," "inotuzumab," and "CAR-T cells," and they discuss "bridging therapy prior to …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The FDA Purple Book document lists product and generic names relevant for alias grouping, including "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• For relapsed or refractory Ph+ ALL, dasatinib (SPRYCEL) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The supplied documents describe broad United States clinical practice guidance for ALL but do not provide the detailed claims-based regimen library, regimen-component grouping rules, aliases, or exhaustive multi-agent …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The documents state that ALL management includes “risk-stratified treatment approaches,” “more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The documents identify methotrexate as being used "as part of a combination chemotherapy maintenance regimen" for ALL, clofarabine for "relapsed or refractory acute lymphoblastic leukemia after at least …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The only explicit relapsed/refractory regimen-related information is that nelarabine is indicated for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)" in patients "whose disease has not …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The supplied documents identify that NCCN ALL guidelines address treatment strategies and management settings for adult and pediatric acute lymphoblastic leukemia, including “risk-adapted therapy,” “frontline and relapsed/refractory management,” …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• The supplied documents do not provide a United States ALL regimen library through 2026-09-21 and do not enumerate induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias grouping frameworks for …CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• Therefore, the available material only partially addresses the requested scope.CMS HCPCS Release FilesBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
• Clofarabine injection is described as "indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents also specifically confirm that HCPCS code J9039 corresponds to “Injection, blinatumomab, 1 microgram” and HCPCS code J9229 corresponds to “Injection, inotuzumab ozogamicin, 0.1 mg.” However, the …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents identify imatinib mesylate tablets for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The FDA Purple Book rows list "Rituxan rituximab," "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and biosimilars "Truxima rituximab-abbs (biosimilar to Rituxan)," …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents also describe administration modality for BLINCYTO and KYMRIAH, including intravenous infusion and continuous IV infusion schedules, but no billing-code linkage is provided.Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents do provide evidence that doxorubicin hydrochloride is indicated for “acute lymphoblastic leukemia” and list multiple methotrexate injectable product variants and preservative-free formulations that could correspond to …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• ANDA dasatinib tablet products with NDC package identifiers "70377-087-11" and "70377-088-11" for 100 mg and 140 mg strengths, respectively …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• Documented mappings include HCPCS code C9449 for blinatumomab defined as "Injection, blinatumomab, 1 mcg," HCPCS code C9028 for inotuzumab ozogamicin defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents do establish branded/generic drug identities and ALL-related treatment use cases: nelarabine injection for relapsed or refractory T-ALL/T-LBL, dasatinib tablets for Ph+ ALL …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• Document 0 identifies SPRYCEL with package NDC "0003-0524-11" and active ingredient "DASATINIB 70 mg/1," while Document 1 identifies SPRYCEL with package NDC "0003-0857-22" and active ingredient "DASATINIB 140 …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• HCPCS mapping is available for imatinib: HCPCS code S0088 is defined as “Imatinib 100 mg — Imatinib, 100 mg.” NDC mappings are provided for branded and generic kinase …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• HCPCS mappings are provided for obecabtagene autoleucel under codes C9301 and Q2058, including descriptions of the leukapheresis and infusion-related therapeutic dose definitions.Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• The documents identify Biocon Pharma Inc. oral dasatinib tablet products with NDC package identifiers 70377-083-11 (20 mg), 70377-084-11 (50 mg) …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• Specifically, NDC 63020-534 corresponds to 45 mg tablets, NDC 63020-536 corresponds to 10 mg tablets …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• A HCPCS mapping is provided for brexucabtagene autoleucel under code C9073, and NDC mappings are provided for branded SPRYCEL (dasatinib) oral tablets with NDC package identifiers 0003-0855-22 and …Dr.Reddy's Laboratories IncUS Food and Drug AdministrationBRISTOL MYERS SQUIBB
• SPRYCEL (dasatinib) for Philadelphia chromosome-positive acute lymphoblastic leukemia is described as an oral tablet therapy: "SPRYCEL TABLET ORAL" and "The recommended starting dosage of SPRYCEL for accelerated phase …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and specify that they are administered intravenously …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• BLINCYTO (blinatumomab) is described as “for injection, for intravenous use,” and is indicated for multiple ALL settings including “relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).” …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The documents identify oral maintenance-regimen therapies for Acute Lymphoblastic Leukemia (ALL), specifically mercaptopurine oral suspension and methotrexate tablets, which implies pharmacy-dispensed oral agents rather than infused medical-benefit products.US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied documents identify multiple Acute Lymphoblastic Leukemia therapies and regimen components through HCPCS injection or CAR-T procedure codes …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The HCPCS entries for obecabtagene autoleucel describe administration-linked billing constructs such as “including leukapheresis and dose preparation procedures” and billing “per therapeutic dose” or “per infusion,” which indicates …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The documents also reference use "in combination with chemotherapy" or as part of a "combination chemotherapy maintenance regimen," indicating that oral agents may be combined with other chemotherapy …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The documents do not provide information about pharmacy-benefit therapies, dual-channel billing, oral-versus-infused routing distinctions in claims systems, or benefit-routing ambiguities affecting line-of-therapy construction.US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The documents identify several Acute Lymphoblastic Leukemia therapies and their coding or dosage-form characteristics …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied document identifies therapies and regimen components used in Acute Lymphoblastic Leukemia treatment studies, including “BESPONSA,” “fludarabine + cytarabine + granulocyte colony-stimulating factor ,” “mitoxantrone + cytarabine …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied documents identify Acute Lymphoblastic Leukemia therapies that are administered as intravenous injections or infusions, including clofarabine and nelarabine.US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied documents identify doxorubicin as a therapy used for "acute lymphoblastic leukemia" and repeatedly describe it as being administered intravenously, including "given intravenously every 21 days," "administered …US Food and Drug AdministrationBRISTOL MYERS SQUIBBNational Library of Medicine (DailyMed)
• The supplied documents identify some supportive or prophylactic agents associated with acute lymphoblastic leukemia care …US Food and Drug AdministrationBulletin du cancerJournal of the National Comprehensive Cancer Network : JNCCN
• The documents mention prophylactic anticoagulation and supportive growth-factor use: in ALL, "Low-molecular-weight heparins (LMWH) at prophylactic doses are recommended as the first-line strategy" and "Direct oral anticoagulants (DOACs) …US Food and Drug AdministrationBulletin du cancerJournal of the National Comprehensive Cancer Network : JNCCN
• The supplied documents mention supportive care in acute lymphoblastic leukemia guidelines, but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor lysis, antiemetic, anti-infective, growth factor …US Food and Drug AdministrationBulletin du cancerJournal of the National Comprehensive Cancer Network : JNCCN
• The supplied documents indicate that NCCN Acute Lymphoblastic Leukemia guidelines include “supportive care considerations,” but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor-lysis, antiemetic, growth-factor …US Food and Drug AdministrationBulletin du cancerJournal of the National Comprehensive Cancer Network : JNCCN
• The Bryant Ranch Prepack labeling states that “Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The NCCN guideline states that the ALL guidelines focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL,” while another document states that “Asparaginase is an integral …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The only explicit NDC/package/manufacturer mapping provided is for IMKELDI: "NDC 81927-201: IMKELDI" from "Shorla Oncology Inc." with packaging "140 mL in 1 BOTTLE (81927-201-01)" and active ingredient "IMATINIB …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The branded product is "SPRYCEL" sponsored by "BRISTOL MYERS SQUIBB," with oral tablet strengths of "20MG," "50MG," "70MG," "80MG," "100MG," and "140MG." Generic labeling is also documented for …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The supplied documents identify representative NDCs, labelers/manufacturers, package presentations, and marketing categories for selected Acute Lymphoblastic Leukemia therapies, specifically Iclusig (ponatinib hydrochloride) and generic dasatinib products from Biocon …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• Takeda Pharmaceuticals America, Inc. markets Iclusig under NDC 63020-535 with bottle presentations containing 30 or 60 film-coated tablets …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The supplied documents identify imatinib mesylate as a therapy used for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including "Adult patients with relapsed or refractory Philadelphia chromosome …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• Novartis Pharmaceuticals Corporation lists Arranon under NDC 0078-0683 with package presentation "50 mL in 1 VIAL (0078-0683-61)"; and E.R.Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• Squibb & Sons, L.L.C. lists SPRYCEL under NDC 0003-0855 with package presentation "1 BOTTLE in 1 CARTON (0003-0855-22) / 30 TABLET in 1 BOTTLE." The documents do not …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• Representative NDCs include 70377-084-11 for 50 mg tablets packaged as "60 TABLET, FILM COATED in 1 BOTTLE," 70377-086-11 for 80 mg tablets packaged as "30 TABLET, FILM COATED …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The documents show that methotrexate tablets from multiple manufacturers are indicated for “acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” demonstrating a multi-source generic …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• Biocon Pharma Inc. markets an ANDA dasatinib product under NDC 70377-088 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (70377-088-11)" and active ingredient strength "DASATINIB 140 …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The supplied documents identify doxorubicin products used for Acute Lymphoblastic Leukemia treatment indications, including branded and generic presentations such as “Doxorubicin Hydrochloride Injection,” “Adriamycin (DOXOrubicin HCl) for Injection …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The supplied documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies relevant to relapsed/refractory or pediatric ALL treatment contexts, including “blinatumomab,” “inotuzumab,” and “PEGasparaginase.” However, the documents do …Bryant Ranch PrepackHOSPIRASHORLA ONCOLOGY
• The documents provide limited dosing and administration details for some therapies used in acute lymphoblastic leukemia (ALL) …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For mercaptopurine used in ALL maintenance therapy, the labeling states that the "recommended starting dose of mercaptopurine oral suspension is 1.5 mg/kg to 2.5 mg/kg (50 mg/m 2 …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The same source specifies administration considerations including oral suspension handling, dosing interval adjustments in renal impairment, and administration instructions.Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For imatinib in relapsed or refractory Philadelphia chromosome positive ALL, the document confirms the indication in adult patients but does not provide ALL-specific dosing schedules or cycle structures.Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The asparaginase consensus document states that "asparaginase is an integral component of therapy" in pediatric-inspired regimens for AYA and adult ALL populations and discusses administration barriers including "limited …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• TECARTUS for adult relapsed/refractory B-cell precursor ALL is administered intravenously after lymphodepleting chemotherapy, with a target dose of "1 × 10 6 CAR-positive viable T cells per kg …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• KYMRIAH is identified as a CD19-directed autologous T-cell immunotherapy for "patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• Clofarabine is described as being administered "52 mg/m 2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle," with cycles repeated …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The methotrexate labeling states that for neoplastic diseases clinicians should "Refer to the prescribing information for disease specific dosing recommendations" and that "Methotrexate Injection is used as part …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The NCCN guideline excerpt states that ALL treatment recommendations include "risk-stratified treatment approaches" and that "patients be treated at specialized centers with expertise in the management of ALL." …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For PEGasparaginase in ALL11 protocol patients, the documents state that “After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For CAR-T cell therapy in relapsed/refractory B-ALL, the documents describe the “bridging period between leukapheresis and CAR-T-cells reinfusion” as a treatment consideration but explicitly note that “there is …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For doxorubicin, the labeling states that for “Metastatic Disease, Leukemia, or Lymphoma” the “recommended dose of doxorubicin when used as a single agent is 60 to 75 mg/m …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For Philadelphia chromosome-positive (Ph+ ALL), the FDA labeling states that SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• 3 months (range 0.1–10 months) for lymphoid blast CML.” Separately, HCPCS coding documentation identifies blinatumomab as an injectable therapy using “HCPCS code J9039” defined as “Injection, blinatumomab, 1 …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• Methotrexate Injection is indicated for ALL "as part of a combination chemotherapy regimen" and is labeled "for intravenous, intramuscular, subcutaneous, or intrathecal use," with additional administration considerations including …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The documents identify several therapies used in Acute Lymphoblastic Leukemia and provide limited administration-related information through HCPCS descriptors and one FDA label …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• For leukemia or lymphoma, doxorubicin is described as a single agent at "60 to 75 mg/m 2 intravenously every 21 days" or in combination therapy at "40 to …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• Methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” and the formulation is …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The materials also note supportive care requirements, use of targeted agents in frontline therapy, and consideration of allogeneic hematopoietic stem cell transplantation in selected higher-risk patients …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• BLINCYTO is administered intravenously and includes hospitalization and steroid premedication requirements tied to treatment cycles for MRD-positive and relapsed/refractory B-cell precursor ALL.Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• BESPONSA is administered by intravenous infusion with cycle-specific dosing on Days 1, 8, and 15, response-dependent cycle lengths, and mandatory corticosteroid, antipyretic, and antihistamine premedication.Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The supplied documents identify HCPCS-coded therapies relevant to Acute Lymphoblastic Leukemia claims and provide limited administration-unit information …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• A Chinese adult ALL guideline states that "systematic treatment regimens" and immunotherapies including antibodies and CAR-T products are used in adult ALL clinical practice …Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• The documents also identify packaging quantities that may be relevant for claim-level regimen identification, including bottles containing 30 or 60 tablets.Apotex CorpHikma Pharmaceuticals USA Inc.American journal of hematology
• Additional governance rules are still required for regimen aggregation, maintenance grouping, and cross-agent line advancement definitions.
• Analysts would still need external governance for regimen aliases, induction versus consolidation categorization, and maintenance normalization.
• HCPCS-coded therapies can support medical-claim exposure identification, while oral kinase inhibitors and maintenance agents may require pharmacy-claim integration using NDCs.
• Mixed oral and infused product representation introduces routing and completeness challenges for line-of-therapy reconstruction.
• Supportive-care filtering and ambiguity resolution will require analyst-defined governance because the source material does not standardize exclusions or routing conventions.
• Methotrexate exposure classification may require indication-sensitive logic to distinguish maintenance therapy from prophylactic or other treatment contexts.
• The evidence references transfusion-related endpoints including platelet and RBC transfusion independence.

Key takeaways

1. The evidence supports therapy-specific cycle and interruption rules for BLINCYTO and BESPONSA but does not provide a complete U.S. claims-based line-of-therapy algorithm.
2. HCPCS/J-code mappings are directly supported for major infused and cellular ALL therapies including blinatumomab, inotuzumab ozogamicin, rituximab, tisagenlecleucel, and brexucabtagene autoleucel.
3. Multiple ALL treatment contexts are subpopulation-specific, including relapsed/refractory CD22-positive B-cell precursor ALL, Ph+ ALL, and relapsed/refractory T-ALL/T-LBL after at least two prior regimens.
4. Representative NDC and package-level evidence exists for oral kinase inhibitors and selected injectables, including ponatinib, dasatinib, clofarabine, nelarabine, and imatinib oral solution products.

Stage 5 — Patient Journey Signals: Discontinuation, Monitoring & Outcomes

Framework steps: Treatment initiation, discontinuation and switching signals; Adverse events and toxicity management; Response, relapse and progression assessment; Monitoring cadence and MRD assessment; End states: transplant, cellular therapy, hospice, death

What happens: This stage establishes how patients with Acute Lymphoblastic Leukemia (ALL) move through treatment monitoring, toxicity management, remission assessment, and downstream outcome states using evidence from chemotherapy, bispecific antibody, antibody-drug conjugate, transplant-related …

Expected output: Discontinuation and adverse-event signals by agent class (Agent class | Signature AE driving discontinuation or switch) · Monitoring and response criteria (Assessment | Tool / criteria) · Patient state model · End-of-journey outcome states · Claims observability table · Key takeaways

Further findings

• BLINCYTO administration includes "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval."National Library of Medicine (DailyMed)
• BLINCYTO labeling references "re-initiations (e.g., if treatment is interrupted for 4 or more hours)."National Library of Medicine (DailyMed)
• Adult ALL induction commonly uses "combination chemotherapy with prednisone, vincristine, and an anthracycline."National Cancer Institute
• Some induction regimens add "asparaginase or cyclophosphamide."National Cancer Institute
• ALL regimen modification included "omission of L-asparaginase" in supplied literature.National Cancer Institute
• Doxorubicin hepatic impairment guidance states "1.2–3 mg/dL 50%" dose reduction.Pfizer Laboratories Div Pfizer Inc
• Doxorubicin hepatic impairment guidance states "3.1–5 mg/dL 75%."Pfizer Laboratories Div Pfizer Inc
• Doxorubicin infusion guidance states "Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur."Pfizer Laboratories Div Pfizer Inc
• Doxorubicin labeling states "Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation."Pfizer Laboratories Div Pfizer Inc
• Maintenance therapy commonly includes oral 6-mercaptopurine (6-MP) and methotrexate (MTX).Open web
• One maintenance study aimed "to describe real-world dose adjustments of MTX and 6-MP during the maintenance therapy in young adults."Open web
• Older or medically frail patients "might not be able to tolerate an intensive induction regimen."American Cancer Society
• Post-treatment monitoring includes "frequent follow-up exams and tests for at least several years."American Cancer Society
• ALL management may include survivorship monitoring for "screening tests for other types of cancer."American Cancer Society
• Treatment phases include induction, consolidation, maintenance, remission surveillance, and relapsed or refractory therapy.National Cancer InstituteAmerican Cancer SocietyNational Library of Medicine (DailyMed)
• Response states described include CR, CRi, MRD positivity, MRD negativity, relapse, and transplant eligibility.National Library of Medicine (DailyMed)Journal of Clinical Oncology
• Claims-derived line-of-therapy reconstruction may follow infusion, encounter, HSCT, and CAR-T utilization patterns.National Library of Medicine (DailyMed)National Cancer InstituteOpen web
• MRD positivity is described as "commonly defined as at least 1 leukemia cell in 10,000 normal cells (expressed as 10-4)."Open web
• MRD laboratory methods described include flow cytometry, PCR, and next-generation sequencing (NGS).Open web
• Flow cytometry MRD assessment requires "the first pull of bone marrow aspiration."Open web
• NGS MRD monitoring can assess "immunoglobulin heavy chain receptor rearrangements or T-cell receptors."Open web
• CIBMTR states "a majority of the disease response criteria are established by an international working group."CIBMTR
• One study reported adult ALL "complete response rates that range from 60% to 90%."Journal of Clinical Oncology
• One cohort reported "436 achieved complete remission (78% +/- 2% for DNR v 74% +/- 3% for ZRB; P = .3)."Journal of Clinical Oncology
• Reported relapse timing included "disease relapse at a median of 58 days after the start of therapy."Journal of Clinical Oncology
• One response duration outcome reported "median duration of 2.2 months."Journal of Clinical Oncology
• Reported outcomes included "3-year disease-free survival."Journal of Clinical Oncology
• BLINCYTO is indicated for "CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy."National Library of Medicine (DailyMed)
• BESPONSA labeling reports "higher post-HSCT non-relapse mortality rate."National Library of Medicine (DailyMed)
• During CAR-T manufacturing, "patients may receive additional chemotherapy to prevent their disease from progressing."Open web
• CAR-T follow-up discussions include "short- and long-term side effects and toxicities," "Infections," and survivorship.Open web
• One source discusses "why some patients die from a CAR T-related toxicity."Open web
• The supplied documents report treatment interruption and discontinuation drivers primarily for the bispecific T-cell engager blinatumomab (BLINCYTO).National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The label states that "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO" and directs clinicians to "Interrupt or discontinue BLINCYTO and …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The supplied document addresses an anthracycline therapy class used in Acute Lymphoblastic Leukemia and reports discontinuation and dose-modification drivers centered on cardiomyopathy, hepatic impairment, infusion complications …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• Reported discontinuation drivers include: “Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy” and “Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The supplied documents report toxicity-driven dose reduction and interruption signals for several ALL therapy classes, but they do not provide a comprehensive cross-class analysis of discontinuation, switching, or …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• For vincristine-based therapy, co-administration with azoles was associated with increased neurotoxicity, CNS toxicity, intensive care use, and dose reduction …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The documents do not define claims-based discontinuation rules, switching algorithms, or specific administrative claims indicators for line-of-therapy construction, although observable claims proxies inferable from the text could include …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The document describes major ALL therapy classes and some treatment-modification contexts, but it does not report administrative-claims algorithms for discontinuation, interruption, switching, or line-of-therapy construction.National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• It states that ALL treatment commonly includes "Long-term chemotherapy (chemo)" and that "Other types of drugs, such as targeted drugs or immunotherapy, are sometimes part of treatment as …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• Dose modification is mentioned for older or medically frail patients, where they "might not be able to tolerate an intensive induction regimen" and "reduced doses of many of …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• Reported discontinuation/interruption or dose-modification drivers include cardiotoxicity risk management, neutropenic fever/infection, delayed blood count recovery, unresolved nonhematologic toxicities, hyperbilirubinemia, and infusion-related extravasation concerns.National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• Observable or inferable administrative claims signals from these events may include delayed treatment cycles, reduced administered dose intensity, therapy restarts after gaps …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The supplied documents report that maintenance therapy for ALL commonly involves oral 6-mercaptopurine (6-MP) and methotrexate (MTX) …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• One study specifically aimed "to describe real-world dose adjustments of MTX and 6-MP during the maintenance therapy in young adults" and noted that these oral therapies "frequently cause …National Library of Medicine (DailyMed)National Cancer InstitutePfizer Laboratories Div Pfizer Inc
• The documents identify several major ALL therapy classes and associated clinically significant adverse events.National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• Conventional induction chemotherapy regimens for adult ALL include "prednisone, vincristine, and an anthracycline," with some regimens adding "asparaginase or cyclophosphamide." BLINCYTO (blinatumomab), a "bispecific CD19-directed CD3 T-cell engager," …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• BESPONSA (inotuzumab ozogamicin), a "CD22-directed antibody and cytotoxic drug conjugate," is associated with "Hepatotoxicity, including fatal and life-threatening VOD," "higher post-HSCT non-relapse mortality," "Myelosuppression," "Infusion Related Reactions," and …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• The supplied documents do not directly describe United States claims-data analyses through 2026-09-21 or explicitly define claims-identifiable adverse-event markers beyond hospitalization recommendations, treatment interruption/discontinuation instructions, dose modifications …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• For doxorubicin, clinically significant adverse events include “Cardiomyopathy,” “Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS),” “Extravasation and Tissue Necrosis,” and “Severe myelosuppression resulting in serious infection …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• The document identifies major ALL therapy classes as "chemotherapy (chemo)," "targeted drugs," and "immunotherapy," noting that "For some people, a stem cell transplant might also be an option." …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• The supplied documents identify major ALL therapy categories and some general disease- and treatment-related clinical issues …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• The National Cancer Institute document states that “Previous chemotherapy and exposure to radiation may increase the risk of developing ALL,” and that “Leukemia may affect red blood cells …National Cancer InstituteNational Library of Medicine (DailyMed)Pfizer Laboratories Div Pfizer Inc
• The supplied document indicates that the CIBMTR Disease Classification Form contains an Acute Lymphoblastic Leukemia section and captures disease-specific response information for hematopoietic cell transplantation reporting, including “disease …CIBMTRNational Cancer InstituteU.S. National Library of Medicine
• The documents describe treatment-response evaluation in adult acute lymphoblastic leukemia (ALL) primarily through remission and survival outcomes after induction and postremission therapy.CIBMTRNational Cancer InstituteU.S. National Library of Medicine
• The document includes laboratory and clinical monitoring elements such as bone marrow assessment, absolute neutrophil count (ANC), platelet count, bilirubin, AST/ALT, and peripheral blast count thresholds.CIBMTRNational Cancer InstituteU.S. National Library of Medicine
• One document identifies a bone marrow biopsy-related assessment element through the LOINC entry "Guidance for biopsy of Bone marrow," indicating that bone marrow biopsy procedures are represented in …CIBMTRNational Cancer InstituteU.S. National Library of Medicine
• Another document references the topic "Novel Therapies for Childhood Acute Lymphoblastic Leukemia" but does not provide details on response assessment criteria, measurable residual disease testing methods, monitoring procedures …CIBMTRNational Cancer InstituteU.S. National Library of Medicine
• MRD positivity is described as “commonly defined as at least 1 leukemia cell in 10,000 normal cells (expressed as 10-4)” and FDA-approved therapeutic decision making included “first or …CIBMTRNational Cancer InstituteU.S. National Library of Medicine
• However, the supplied material does not describe the positioning of allogeneic hematopoietic stem cell transplant or CAR-T therapy within the ALL treatment journey, does not define terminal pathway …National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer Institute
• The label states, “For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles,” with a possible third cycle if …National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer Institute
• The documents position allogeneic bone marrow transplant within the treatment journey for adult ALL as a consideration after induction or other chemotherapy responses because “remissions are generally short …National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer Institute
• ALL populations, do not describe post-treatment outcome states or bridge pathways, and do not provide claims-based procedure identification methods or coding approaches through 2026-09-21.National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer Institute
• The documents position CAR-T therapy for ALL primarily in the relapsed or refractory setting and describe bridging chemotherapy before infusion, while also discussing survivorship, toxicities, infections …National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer Institute
• One document states that “Three CAR T-cell products have been approved by the FDA to treat patients with relapsed or refractory B-cell ALL,” and another states that “While …National Library of Medicine (DailyMed)Journal of Clinical OncologyNational Cancer Institute
• The document states that for adult ALL, “Treatment for ALL typically lasts for at least 2 years,” and that after treatment ends patients require “frequent follow-up exams and …American Cancer SocietyNational Cancer InstituteU.S. National Library of Medicine
• The document states that induction therapy commonly uses multiagent chemotherapy regimens and mentions supportive care measures and hematopoietic growth factors during remission-induction therapy.American Cancer SocietyNational Cancer InstituteU.S. National Library of Medicine
• No laboratory surveillance schedules, imaging frequency, toxicity-monitoring cadence, remission follow-up intervals, or claims-based monitoring definitions are provided in the supplied text.American Cancer SocietyNational Cancer InstituteU.S. National Library of Medicine
• The only monitoring-related activity identifiable from the document is the existence of a LOINC-coded bone marrow pathology biopsy report: LOINC code 33721-2 is defined as "Bone marrow Pathology …American Cancer SocietyNational Cancer InstituteU.S. National Library of Medicine
• One document states that "Over the course of 2 to 3 years, patients undergo treatment for induction, consolidation, maintenance …American Cancer SocietyNational Cancer InstituteU.S. National Library of Medicine
• MRD-positive or MRD-negative
• Treatment response assessment includes CR, CRi, bone marrow blast assessment, peripheral blood count recovery, and MRD-related milestones.
• Monitoring cadence is only partially described, with frequent follow-up exams and tests after therapy and no standardized claims-based cadence framework defined.
• Claims observability is strongest for hospitalization, transfusion, bone marrow biopsy encounters, treatment interruption, and transplant-related utilization.
• Administrative claims data are more reliable for identifying utilization-based journey events than clinical response states.

Key takeaways

1. Line-of-therapy logic must distinguish planned BLINCYTO 14-day off-treatment intervals from true discontinuation gaps.
2. Claims algorithms should treat HSCT and CAR-T encounters as major downstream transition states requiring separate pathway flags.
3. CR, CRi, and MRD outcomes require laboratory or registry linkage because administrative claims lack direct response-result capture.
4. Dose reductions, infusion interruptions, hospitalization, transfusions, and extended cycles are primary observable toxicity proxies across ALL therapies.

Stage 6 — Unmet Need Synthesis & QA Validation

Framework steps: Compare guidelines vs labels vs literature vs real-world evidence; Identify unmet needs and evidence gaps; Surface contradictions between sources; Document assumptions and limitations; Run QA and SME review readiness assessment

What happens: This stage consolidates unresolved evidence gaps, methodological constraints, observability limitations, and QA considerations affecting construction and validation of claims-derived lines of therapy for Acute Lymphoblastic Leukemia (ALL) in United States administrative data through 2026-09-21. It establishes where published evidence supports only partial inference, where treatment …

Expected output: Unmet-need synthesis (Gap area | Description) · Contradiction table · Assumptions · Limitations · QA checklist · QA / SME sign-off checklist · Readiness assessment

Further findings

• 35/154 (22.7%) patients switched from 1 L asparaginase to recombinant Erwinia after frontline PEG/CAL-PEG exposure.Journal of medical economics
• Protocol treatment was discontinued when Philadelphia chromosome-positive disease was later identified during adult Ph- B-ALL evaluation.Hematology (Amsterdam, Netherlands)
• The supplied evidence did not provide explicit NCCN-to-FDA label comparisons or temporal FDA label evolution through 2026-09-21.Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center
• Response assessment included “NGS MRD negative,” requiring specialized measurable residual disease testing workflows.National Cancer Institute (NCI)
• Relapse monitoring referenced “functional CART persistence” alongside blood and bone marrow testing and NGS monitoring.National Cancer Institute (NCI)
• Transplant eligibility evaluation included “co-morbidities precluding myeloablative HCT.”National Cancer Institute (NCI)
• Acute leukemia diagnosis required “flow cytometric immunophenotyping” beyond morphology alone in ambiguous cases.The Libyan journal of medicine
• Immunophenotyping evaluation included assessment of “aberrant antigen expression” for lineage assignment.The Libyan journal of medicine
• The supplied evidence did not define maintenance therapy rules or combination-therapy sequencing standards for claims analyses.Journal of medical economicsHematology (Amsterdam, Netherlands)
• It describes a claims-based distinction between frontline and second-line asparaginase therapy, specifically defining patients who "switched from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) …Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center
• However, the document does not discuss NCCN recommendations, FDA-approved labels, guideline-label discordance, maintenance therapy definitions, off-label sequencing recommendations, combination therapy assumptions, or temporal label changes through 2026-09-21.Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center
• It states that in adult Philadelphia chromosome-negative B-cell ALL, “Blinatumomab is currently the only targeted agent approved for frontline treatment,” while also describing investigational and emerging frontline use …Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center
• The document also describes blinatumomab use in specific frontline consolidation and MRD-positive CR1 settings, which may affect claims-based line-of-therapy interpretation …Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center
• It does, however, describe uncertainty in adult ALL regimen selection and sequencing, stating that "The standard treatment for adults with ALL consists of many chemotherapy drugs that are …Journal of medical economicsHematology (Amsterdam, Netherlands)Memorial Sloan Kettering Cancer Center
• The documents identify several clinically relevant concepts used in acute lymphoblastic leukemia (ALL) management that depend on molecular testing, remission assessment, relapse assessment …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• These include molecular and cytogenetic subtype information such as “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL),” “ZNF384 fusion transcripts,” “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations.” The documents …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• The document indicates that several clinically relevant concepts for B-ALL management depend on biomarker testing, bone marrow evaluation, flow cytometry, NGS monitoring, imaging, or physician assessment rather than …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• Relapse risk and relapse monitoring are described as requiring “blood and bone marrow tests,” “NGS monitoring,” and assessment of “functional CART persistence,” while transplant eligibility depends on factors …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• The supplied document indicates that accurate acute leukemia diagnosis requires information beyond morphology alone, specifically "flow cytometric immunophenotyping" and assessment of "aberrant antigen expression." The document also notes …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• The supplied documents identify several clinically relevant concepts in Acute Lymphoblastic Leukemia (ALL) that are associated with prognosis, treatment selection, disease spread …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• The documents mention prognosis-related factors, tests examining blood and bone marrow, spread to the central nervous system, and targeted therapeutics development …Hematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer Institute (NCI)
• Claims-only ALL analyses will require explicit assumptions for line transitions, remission, relapse, and discontinuation because clinically important disease and response variables depend on molecular and laboratory assessments.
• Cohort logic must preserve subgroup qualifiers such as Ph+ ALL and Ph- B-ALL to avoid inappropriate generalization.
• Treatment sequencing standardization Adult ALL treatment lacks a single standardized regimen approach because “The standard treatment for adults with ALL con Regimen grouping and line attribution may vary …
• Limited claims-based line definition evidence The supplied evidence provides only isolated examples of claims-oriented sequencing definitions, including patients who Claims-based line-of-therapy algorithms may require operational assumptions due to …
• Population heterogeneity Evidence distinguishes molecular and disease subgroups including “Ph+ ALL,” “Philadelphia (Ph) chromosome-negative B-cel Subpopulation-specific evidence cannot be generalized across all ALL populations without preserving subgroup qualifiers.
• Relapse characterization limitations Outcomes literature reports that “nearly half of patients relapsed within 3 years,” but no standardized claims-based rel Longitudinal relapse detection and post-relapse sequencing may be …
• The supplied document contains limited direct evidence on guideline-label divergence in ALL, but identifies tensions between subgroup-specific approval statements, heterogeneous regimen practices, and sparse sequencing definitions.
• The available evidence supports cautious interpretation of guideline and label applicability because subgroup restrictions and heterogeneous treatment practices are common in ALL.
• One source states that “Blinatumomab is currently the only targeted agent approved for frontline treatment,” but the sup Preserve the exact subpopulation scope when interpreting frontline targeted therapy …
• Standardization of adult ALL regimens NCCN-related commentary describes ALL treatment as “one of the most complex and difficult” hematologic malignancies.
• The evidence states “there is no standard which drugs to give and how to combine them.” Use transparent regimen grouping logic because no universal adult ALL sequencing standard …
• Subpopulation applicability Several cited studies are restricted to “adults with Ph- B-ALL.” The evidence also distinguishes “Ph+ ALL” and fusion-defined subtypes including “EP300::ZNF384” and “TCF3::ZNF384.” Maintain subgroup-specific attribution …
• The supplied evidence highlights that ALL claims-based modelling is constrained by incomplete observability of molecular subtype, MRD status, remission assessment, and standardized relapse logic.
• Downstream modelling should emphasize transparent sequencing assumptions, subgroup preservation, and explicit handling of unobservable clinical states.

Key takeaways

1. Cohort logic must preserve Ph+ and Ph- subgroup exclusions throughout sequencing and outcome analyses.
2. Claims-based remission and relapse definitions require proxy assumptions because MRD, NGS, and immunophenotyping results are not directly observable.
3. Line-of-therapy frameworks must document assumptions for asparaginase switching, discontinuation, and investigational frontline targeted therapy use.
4. Validation workflows should review transplant eligibility, CNS/EMD classification, and CART persistence concepts separately from claims-derived endpoints.

Open items

• In United States administrative claims-based analyses of all patients with Acute Lymphoblastic Leukemia through 2026-09-21, what are the principal unmet needs and evidence limitations …
• In United States real-world claims data for all patients with Acute Lymphoblastic Leukemia through 2026-09-21, what evidence gaps and methodological limitations prevent reliable characterization …

Consolidated one-page view

Sources referenced

• FDA Drug Labeling (openFDA) — Alembic Pharmaceuticals Limited · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ad6056-0… 41 items
• ESMO — Blood advances · pubmed.ncbi.nlm.nih.gov/41670627/ 40 items
• DailyMed — National Library of Medicine (DailyMed) · dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38b482a8-9… 37 items
• National Cancer Institute (NCI) PDQ — National Cancer Institute · www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq 37 items
• FDA Drugs@FDA (openFDA) — TAKEDA PHARMS USA · www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=ove… 22 items
• NLM Clinical Tables (HCPCS) — U.S. National Library of Medicine · clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=G0364 15 items
• NLM Clinical Tables (ICD-10-CM) — U.S. National Library of Medicine · clinicaltables.nlm.nih.gov/api/icd10cm/v3/search?terms=C91.00 13 items
• NLM Clinical Tables (LOINC) — U.S. National Library of Medicine · loinc.org/54226-6/ 11 items
• CMS HCPCS Release Files · www.cms.gov/medicare/coding-billing/healthcare-common-proce… 10 items
• NCI SEER — National Cancer Institute, Surveillance, Epidemiology, and End Results Program · seer.cancer.gov/statfacts/html/alyl.html 10 items
• Orphanet / Orphadata — Orphanet · www.orpha.net/en/disease/detail/513 10 items
• FDA NDC Directory (openFDA) — Takeda Pharmaceuticals America, Inc. · ndclist.com/ndc/63020-535 9 items
• FDA Purple Book · purplebooksearch.fda.gov/ 7 items
• CMS ICD-10-CM Release Files · www.cms.gov/medicare/coding-billing/icd-10-codes 6 items
• WHO · applications.emro.who.int/imemrf/J_Royal_Med_Serv/J_Royal_M… 6 items
• CDC / NCHS · www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6636a3.pdf 5 items
• FDA · www.fda.gov/drugs/resources-information-approved-drugs/fda-… 5 items
• NLM Clinical Tables (ICD-9-CM) — U.S. National Library of Medicine · clinicaltables.nlm.nih.gov/api/icd9cm_dx/v3/search?terms=20400 5 items
• WHO Global Health Observatory — World Health Organization · ghoapi.azureedge.net/api/CANCERSURVIVAL_CHILDREN_LEUKAEMIA 2 items
• ASCO — Journal of Clinical Oncology · doi.org/10.1200/jco.2018.36.30_suppl.50 32 items
• ASH / Blood (American Society of Hematology) — American Society of Hematology · pubmed.ncbi.nlm.nih.gov/41670624/ 29 items
• Europe PMC — Hematology (Amsterdam, Netherlands) · pubmed.ncbi.nlm.nih.gov/42711755/ 28 items
• ClinicalTrials.gov — Memorial Sloan Kettering Cancer Center · clinicaltrials.gov/study/NCT01920737 24 items
• PubMed — Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · pubmed.ncbi.nlm.nih.gov/42763307/ 10 items
• American Cancer Society · www.cancer.org/cancer/types/acute-lymphocytic-leukemia/trea… 7 items
• CIBMTR · cibmtr.org/Files/Data-Operations/Retired-Forms-Manuals/2402… 2 items
• Open Web (Supplementary) — Open web · www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq 73 items

Coverage: every number and code in the 39 gathered answers and the finding cards appears in the tables or the findings above. 262 lines were added by the coverage check.